Pierre Heudel, Oncologist and Director of Centre Léon Bérard, shared a post on LinkedIn:
“Hyperprogression under immunotherapy: the essential contribution of real-world data in oncology.
Immune checkpoint inhibitors have transformed the management of many solid cancers. But in some patients, they can be accompanied by a rapid and unexpected acceleration of the disease: hyperprogressive disease.
The French multicenter study HYPERPROG, published in Cancer Communications, illustrates the value of Real-World Evidence to better understand these rare but critical situations.
From more than 13,000 patients treated with immunotherapy in 4 French centers, the authors identified 57 confirmed cases of hyperprogression.
The results show a very early evolution:
- median time to onset: 31 days;
- nearly 77% of cases in the first two months;
- Median overall survival: about 4 months.
These results are a reminder that RWDs are not only used to complement clinical trials: they also make it possible to detect real, sometimes brutal, trajectories encountered in daily practice.
In oncology, better use of real-life data means better identifying warning signs, better monitoring patients at risk and adapting treatment decisions more quickly.”
Title: Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences
Authors: Damien Bruyat, Nicolas Girard, Pierre Heudel, Nicolas Penel, Marie-Cécile Le Deley, Issaga Diallo, Jean-Marie Boher, Christophe Zemmour, Brice Chanez, Anne Madroszyk, Gwenaelle Gravis, Emilien Billon, Aaron Lisberg, Bérénice Collineau, Mathilde Beaufils, Anthony Gonçalves, Manuel Tejeda, Anne-Sophie Chrétien, Philippe Rochigneux
Read The Full Article
Other articles about immunotherapy on OncoDaily